The bisphosphonate odyssey. A journey from chemistry to the clinic

Phosphorus, Sulfur and Silicon and Related Elements

Volumn 144-146, Issue , 1999, Pages 793-820

  Graham, R ^a   Russell, G ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0033482823     PISSN: 10426507     EISSN: None     Source Type: Journal    
DOI: 10.1080/10426509908546364     Document Type: Article

References (137)

1. Russell RGG and Rogers MJ. Bisphosphonates. From the laboratory to the clinic and back again. Journal of Bone and Mineral Metabolism. In press
2. Bijvoet O, Fleisch H, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone. Elsevier Science B.V. 1995.
3. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the Patient, Third Edition, The Parthenon Publishing Group, New York, NY, 1997.
4. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998, 19(1):80-100.
5. Ebetino FH, Francis MD, Rogers MJ, Russell RGG. Etidronate. Mechanisms of action of etidronate and other bisphosphonates. Revs in Contemp Pharma, 1998, 9:233-243.
6. Rogers MJ, Watts DJ, Russell R.G.G. Overview of bisphosphonates. Cancer 1997; 80/8:1652-1669.
7. Russell RGG, Rogers MJ. Introduction to bisphosphonates and the clinical pharmacology of alendronate. Brit J Rheumatol 1997; 36(S):10-14.
8. Johnson S, Johnson FN (Eds). Etidronate in Osteoporosis. Revs in Contemp Pharm Vol 9. 1998.
9. Geddes AD, D'Souza SM, Ebetino FH, Ibbotson KJ. Bisphosphonates: structure-activity relationships and therapeutic implications. Bone Min Res 1994;8:265-306.
10. Sietsema WK, Ebetino FH, Salvagno AM, Bevan JA. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exptl Clin Res 1989;15:389-396.
11. Francis, RM. Oral Bisphosphonates in the treatment of osteoporosis: A review. Curr Thera Res 1998;56:831-851.
12. Papapoulos, SE. Pharmacodynamics of bisphosphonates in man. Chapter 15 in Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone. Elsevier Science B.V. 1995.
13. Bijvoet O, Fleisch H, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone. Elsevie Science B.V. 1995.
14. Menschutkin N 1865 Ueber die Einwirkung des Chloracetyls auf phosphorige Saure. Ann Chem Pharm 133:317-320.
15. Smith R, Russell RGG, Bishop M. 1971. Diphosphonates and Paget's disease of bone. Lancet 1:945-947.
16. Von Baeyer, H, Hofmann KA 1897 Acetodiphosphorige Saure. Berichte Dtsch. Chem. Ges. 20: 1973-1978.
17. Blomen LJMJ. 1995 Discovery and history of the non-medical uses of bisphosphonates. Chapter 7 in Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone, Elsevier Science B.V. 111-124.
18. Fleisch H, Neuman WF. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. 1961. Am. J. Physiol. 200:1296-1300.
19. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. 1962. Am. J. Physiol. 203:671-675.
20. Fleisch H, Russell, RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 1966; 212:901-903.
21. Russell, R.G.G. and Hodgkinson, A. (1966) The urinary excretion of inorganic pyrophosphate by normal subjects and patients with renal calculus. Clinical Science, 31, 51-62.
22. Russell RGG. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet, 1965; ii: 461-464.
23. Russell RGG, Bisaz S, Donath A, Morgan DB, and Fleisch H. Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta and other disorders of bone. J Clin Invest 1971; 50: 961-969.
24. 3 in rats. Clinical Science, 35, 363-372.
25. Fleisch H, Russell RGG, Bisaz S, Casey PA, Muehlbauer RC 1968 The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif Tissue Res 2:10-10A.
26. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 1969, 165 :1264-6.
27. Heisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 1969;165:1262-4.
28. Jung A, Bisaz S, Fleisch H 1973 The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res 11:269-280.
29. Fleisch HA, Russell RGG, Bisaz S, Muehlbauer RC, Williams DA. 1970. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur. J. Clin. Invest. 1:12-18.
30. Fleisch, H., Maerki, J. and Russell, R.G.G. (1966). Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proceedings of the Society of Experimental Biology, 122, 317-320.
31. Russell RGG, Muhlbauer RC, Bisaz S, Williams D.A Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res 1970;6;83-196.
32. Schenk R, Merz WA, Muhlbauer R, Russell RGG, Fleisch H 1973 Effect of ethane-1-hydroxy-1,1 -diphosphonate (EHDP) and dichloromethylene diphosphonate (C12MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res 11:196-214.
33. Trechsel U, Stutzer A, and Fleisch H. Hypercalcaemia induced with an arotinoid in thyroparathyroidectomised rats. A new model to study bone resorption in vivo. J. Clin. Invest. 1987; 80: 1679-1686.
34. Stutter A, Fleisch H, and Trechsel U. Short and long term effects of a single dose of bisphosphonates on retibnoid-induced bone resorption in thyroparathyroidectomised rats. calc. Tiss. Int. 1988; 43: 294-299.
35. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. 1983. Structure-activity relationships of various bisphosphonates. Calcif Tiss Int 35:87-99.
36. Flanagan AM, Chambers TJ 1989 Dichloromethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP-coated bone. Bone Miner 6:33-43.
37. Schenk R, Eggli P, Fleisch H, Rosini S. 1986. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calc Tiss Int 38:342-349.
38. Gasser AB, Morgan DB, Fleisch HA, Richelle LJ 1972 The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci 43:31-45.
39. Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA 1980 Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int 32:145-157.
40. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
41. Muehlbauer RC, Russell RGG, Williams DA, Fleisch H 1971 The effects of diphosphonates, polyphosphates and calcitonin on ìimmobilisation osteoporosisî in rats. Europ J Clin Invest 1:336-344.
42. Ferretti JL Effects of bisphosphonates on bone biomechanics. Chapter 31 In: Bisphosphonates on bone (O. Bijvoet, H.A. Fleisch, R.E. Canfield and R.G.G. Russell, eds), Elsevier Science B.V. 1995.
43. Martodam RR, Thornton KS, Sica DA, D'Souza SM, Flora L, Mundy GR 1983 The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor. Calcif Tissue Int 35:512-519.
44. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T 1995 Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 55 :3551-3557.
45. Mundy GR, Yoneda T 1995 Facilitation and suppression of bone metastasis. Clin Orthop Relat Res 312:34-44.
46. Mundy, Gregory R. (1998) Bisphosphonates as anticancer drugs. The New England Journal of Medicine, 339, 398-400.
47. Smith R Ectopic Calcification and ossification Chapter 31 In: Bisphosphonate on bones (O. Bijvoet, H.A. Fleisch, R.E. Canfield and R.G.G. Russell, eds), Elsevier Science B.V. 1995.
48. Fogelman I, Bessent RG, Turner JF, Citrin DL, Boyce IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl. Med 1978; 19:270-5.
49. Francis MD, Fogelman, I. 99mTc-diphosphonate uptake mechanisms on bone. In: Fogelman I, ed., Bone Scanning in Clinical Practice 1987 Springer Verlag, London, pp. 1-6.
50. Russell RGG, Smith R Preston C, Walton RJ, Woods CF. Diphosphonates in Paget's disease. Lancet 1974 1:894-98.
51. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;336:558-566.
52. Douglas DL, Russell RGG, Preston CJ, Prenton MA, Duckworth T, Kanis JA, Preston FE, Woodhead JS 1980 Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet 1 : 1043-1047.
53. Coukell, AJ, and Markham A. (1998). Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-indiced hypercalcaemia and Paget's disease of bone. Drugs & Aging, 12, 149-168.
54. Singer, FR., Clemens, TL., Eusebio RE., Bekker, PJ. (1998). Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. Journal of Clinical Endocrinology and Metabolism, 83, 1906-1910.
55. Siris ES., Chines AA., Altman RD., Brown JP., Johnston C.C, Lang R, McClung MR., Mallette LE, Miller PD., Ryan WG, Singer FR., Tucci, JR., Eusebio, RA., Bekker P.J. (1998). Risedronate in the treatment of Paget's disease of bone: An open label, multi-center study. Journal of Bone and Mineral Research, 13, 1032-1038.
56. Mee AP, Paramyxoviruses and Paget's disease: Affirmative view. Bone 24. ...-... In press 1999.
57. Paterson AD, Kanis JA, Cameron EC, Douglas DL, Beard DJ, Preston FE, Russell RGG 1983 The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. British Journal of Haematology 54: 121-131.
58. Ralston, S.H., Gallacher, S.J., Patel, U., Fraser, W.D., Dryburgh, F.J., Boyle, I.T. (1989) Comparison of three bisphosphonates in cancer-associated hypercalcaemia. Lancet, ii, 1180-1182.
59. McCloskey, E.V., MacLennan, I.C.M., Drayson, M., Chapman, C., Dunn, J., Kanis, J.A. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults. Br J Haem 1998, 100:317-325.
60. Berenson, J.R., Lichtenstein, A., Porter, L., Dimopoulos, M.A., Bordoni, R., George, S., Lipton, A., Keller, A., Ballester, O., Kovacs, M.J., Blacklock, M.B., Bell, R., Simeone, J., Reitsma, D.J., Heffernan, M., Seaman, J., Knight, R.D. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. New England Journal of Medicine, 334, 488-493 (1996).
61. Diel IJ, Solomayer E-F, Costa SD, Gollan C, Goerner R, Wallwiener D, Kaufmann M, Basten G. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998;339, 357-363.
62. Storm T, Thamsborg G, Steiniche T et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. New Engl J Med 1990;322:1265-71.
63. Watts NB, Harris ST, Genant HK et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73-79.
64. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriquez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
65. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535-1541.
66. van Staa TP, Abenhain L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Brit J Rheum 1998; 37: 87-94.
67. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-1480.
68. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:381-387.
69. Saag KG, Emkey K, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman U, Delmas PD, Malice M-P, Czachur M, Daifotis A.G. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-229.
70. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;33:947-952.
71. Adami S, Zamberlan N. Adverse effects of bisphosphonates Drug Safety 1996; 14 :158-170.
72. van Staa, TP. Post marketing survey with ICT-etidronate therapy. Reviews in Contemporary Pharmacology, 1998;9:277-286.
73. DeGroen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;355:1016-1021.
74. Ebrahimpour A, Francis MD. 1995. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. In: Bisphosphonate on bones (O. Bijvoet, H.A. Fleisch, R.E. Canfield and R.G.G. Russell, eds), Elsevier Science B.V.
75. Muehlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H 1991. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011.
76. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res 1988;4:775-781.
77. Goa, KL., Balfour, JA. (1998) Risedronate. Drugs and Aging, 13, 83-91.
78. Green JR, Mueller K, Jaeggi KA 1994 Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 9:745-751.
79. Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus, Sulfur and Silicon 1996; 109/110:217-220.
80. van Beek E, Lowik C, Oue I, Papapoulos, S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res 1996;11:1492-149.
81. Hughes DE, MacDonald BR, Russell RGG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Inves. 1989;83:1930-1935.
82. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Wil Thesing C, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986;1:27-39.
83. Löwik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Treslong-de Groot H, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts : the effect of a bisphosphonate. J Bone Miner Res 1988;3:185-192.
84. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997;12:869-879.
85. Masarachia P, Weinreb M, Balena R, Rodan GA. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone 1996;19:281-290.
86. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone 1995;16:235-245.
87. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Min Res 1990;5:31-40.
88. Sahni M, Guenther H, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest 1993;91:2004-2011.
89. Niskikawa M, Akatsu T, Katayama Y, Yasutomo Y, Kado S, Kugai N, Yamamoto M, Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone 1996;18:9-14.
90. Yu X, Scholler J, Foged NT. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone 1996;19:339-345.
91. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclasl-mediated resorption. Endocrinology 1996 ;137 :2324.
92. Ito, M., Chokki, M., Ogino, Y., Satomi, Y., Azuma, Y., Ohta, T., Kiyoki, M. Comparison of the cytotoxic effects of bisphosphnates in vitro and in vivo. Calcif. Tiss. Int. 1998, 63:143-147.
93. Breuil, V., Cosman, F., Stein, L., Horbert, W., Nieves, J., Shen, V., Lindsay, R., Dempster, D.W. Human osteoclast formation and acivity in vitro: effects of alendronate. J Bone Miner Res 1998, 13:1721-1729.
94. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce, BF. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478-1487.
95. Selander KS, Mönkkönen J, Karhukorpi E-K, Härkönen P, Hannuniemi R, Väänänen HK. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996;50:1127-1138.
96. Rogers MJ, Chilton KM, Coxon F, Lawry J, Smith MO, Suri S, Russell RGG. Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J Bone Miner Res 1996;11:1482-1491.
97. Coxon, F.P., Benford, H.L., Russell, R.G.G., Rogers, M.J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol. Pharmacol. 1998, 54:631-638.
98. Shipman CM, Rogers MJ, Apperley JF, Russell RGG, Croucher PJ. Bisphosphonates induce apoptosis in human myeloma cells; a novel anti-tumour activity. Brit J Haematol 1997;98:665-672.
99. Shipman, C.M., Croucher, P.I., Russell, R.G.G., Rogers, M.J. The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway. Cancer Res. 1998, 58:5294-5297.
100. 2MBP-coated bone. Bone and Mineral 1986;6:33-43.
101. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991; 88 :2095-2105.
102. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, Zhang D, Barbier A, Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 1995; 17:137-144.
103. Schmidt A, Rutledge SJ, Endo N, Opas EE, Tanaka H, Wesolowski G, Leu CT, Huang Z, Ramachandaran H, Rodan SB, Rodan GA. Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci 1995; 93:3068-3073.
104. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatases: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996; 11:535-543.
105. Olpas EE, Rutledge SJ, Golub E, Stern A, Zimolo Z, Rodan GA, Schmidt A. Alendronate inhibition of protein-tyrosine-phosphatase-Megl. Biochem Pharmacol 1997;54:721-727.
106. Murakami H, Takahashi N, Tanaka S, Nakamura I, Udagawa N, Nakajo S, Nakaya K, Abe M, Yuda Y, Konno F, Barbier A, Suda T. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone 1997; 20:399-404.
107. + ATPase. J Bone Miner Res 1996;11:1498-1507.
108. Carano A, Teitelbaum SA, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J. Clin. Invest. 1990; 85:456-461.
109. Zimolo Z, Wesolowski G, Rodan, GA.. Acid extrusion is induced by osteoclast attachment to bone. J Clin. Invest 1995;96:2277-2283.
110. Felix R, Russell RGG, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta 1976;429:429-438.
111. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone 1987;8:179-189.
112. Rogers MJ, Watts DJ, Russell RGG, Ji X, Xiong X, Blackburn GM, Bayless A, Ebetino FH. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res. 1994;9:1029-1039.
113. Rogers MJ, Xiong X, Brown RJ et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995;47:398-402.
114. Rogers MJ, Ji X, Russell, RGG, Blackburn GM, Williamson M.P, Bayless AV, Ebetino FH, Watts DJ. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994; 303:303-311.
115. Rogers M, Russell RGG, Blackburn GM, Williamson MP, Watts DJ. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992;189:414-423.
116. Rogers MJ, Brown RJ, Hodkin V, Russell RGG, Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996;224:863-869.
117. Pelorgeas S, Martin J-P, Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. Biochem Pharmacol 1992; 44:2157-2163.
118. Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1996;12:1358-1367.
119. Auriola S, Frith J, Rogers MJ, Koivuniemi A, Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B 1997;704:187-195.
120. Frith JC, Coxon FP, Auriola S, Mönkkönen J, Yu X, Scheven B, Russell RGG & Rogers MJ. The molecular mechanism of action of clodronate in osteoclasts. J Bone Miner Res 1998, 23(Suppl):S551.
121. Rogers MJ, Xiong X, Ji X, Mönkkönen J, Russell RGG, Blackburn GM, Williamson MP, Watts DJ. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res 1997;14:625-630.
122. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annual Rev Biochem 1996; 65:241-69.
123. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 1992;70:389-399.
124. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell 1992;70:401-410.
125. Zerial M, Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol 1993;5:613-620.
126. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, Shibasaki Y, Morii N, Narumiya S, Takahashi N, Suda T. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci 1995;108:2285-2292.
127. Marshall C. Protein prenylation: a mediator of protein-protein interactions. Science 1993;259:1865-1866.
128. Luckman SP, Hughes DE, Coxon F.P, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
129. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998;13:1668-1678.
130. Fisher, J.E., Rogers, M.J., Halasy, J.M., Luckman, S.P., Hughes, D.E., Masarachia, P.J., Wesolowski, G., Russell, R.G.G., Rodan, G.A., Reszka, A.A. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc. Natl. Acad. Sci. 1999, 96:133-138.
131. Hall, A. Rho GTPases and the actin cytoskeleton. Science 1998, 279:509-514.
132. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-hydroxy-3-(methylpentylamino)-propylidene-1,1 -bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Research 1996; 46:759-762.
133. Amin D, Cornell SA, Gustafson SK, Needle SJ, Ullrich JW, Bilder GE, Perrone MH. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992;33,:1657-1663.
134. van Beek E, Pieterman E, Cohen L, Löwik C, and Papapoulos S. (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochemical and Biophysical Reserch Communications, 255, 491-494.
135. Sauty A, Pecherstorfer M, Zimmerroth I, Fioroni P, Juillerat L, Markert M, Ludwig H, Leuenberger P, Burckhardt P, Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone 1996;18:133-139.
136. Schweitzer DH, Oostendorp-van de Ruit M, van der Pluijm G, Lowik CWGM, Papapoulos SE.. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohy-droxypropylidene bisphosphonate. J Bone Miner Res 1995;10:956-962.
137. Adami S, Bhalla AK, Dorizzi R et al. The acute-phase response after bisphosphonate administration. Calcif Tissue Int 1987; 41:326-31.